RPG Life Sciences Limited announces an acquisition

The disclosed consideration for the Raghava Life Sciences API and intermediates business is up to Rs 135 crore; the announcement does not establish that the full amount has already been settled. ^[1]

Net debt-to-equity impact

The latest reported quarterly position is Q1 FY27. On a consolidated basis, RPG Life Sciences reported:

• Total debt: Rs 20.00 crore ^[2]
• Cash and equivalents: Rs 150.46 crore ^[3]
• Net debt: negative Rs 130.46 crore, i.e. net cash ^[4]
• Net debt-to-equity: negative 0.22x ^[5]
• Total equity: Rs 605.38 crore ^[6]

Mechanical full-cash-outflow scenario: assuming the maximum Rs 135 crore is paid from existing consolidated cash, with no simultaneous equity funding, debt change, or accounting adjustment:

• Pro-forma cash: Rs 150.46 crore minus Rs 135 crore = Rs 15.46 crore
• Pro-forma net debt: Rs 20.00 crore minus Rs 15.46 crore = Rs 4.54 crore
• Pro-forma net debt-to-equity: Rs 4.54 crore / Rs 605.38 crore = approximately 0.01x, versus negative 0.22x reported in Q1 FY27.

Thus, the maximum outflow would reduce the net-cash surplus by Rs 135 crore and move leverage by approximately 0.23x, from a net-cash position to a marginal net-debt position. This is a pro-forma calculation, not the company’s reported post-acquisition ratio. The transaction announcement says the acquisition will be funded in line with RPG Active Pharma’s recent equity raise, so the actual consolidated impact could be less adverse if that funding was raised separately rather than drawn from existing cash. ^[7]

The acquisition filing does not disclose the acquired API business’s historical revenue or EBITDA margins, and it also does not provide a directly comparable existing API-segment margin for RPG Life Sciences. The filing only confirms the slump-sale acquisition from Raghava Life Sciences and states that the transfer became effective on 16 September 2026. ^[8]

RPG Life Sciences’ reported EBITDA margins are company-level figures, not API-segment margins—for example, standalone EBITDA margin was 24.4% in Q1 FY27. ^[9] Using this as a proxy for the API segment would be misleading because the company’s other businesses are included.

Implication: The acquisition’s margin accretion or dilution cannot be assessed from the completion filing alone. The relevant missing disclosures are the acquired business’s historical revenue and EBITDA, plus RPG’s pre-acquisition API-segment revenue and EBITDA or margin on a consistent period and accounting basis.

Yes. The acquisition adds identifiable API manufacturing and regulatory assets, but the disclosure supports EU-GMP and WHO-GMP approvals—not USFDA approval. It brings approximately 300 KL of installed capacity, a dedicated R&D setup, 22 commercialised APIs and seven development-stage assets into RPG Active Pharma’s platform. This broadens the API portfolio and manufacturing footprint, although the filing does not quantify the post-acquisition product mix by revenue or product category.

The intended integration levers are backward integration, higher capacity utilisation, cost synergies and selected product transfers across the acquired business, Actis and the wider RPG Active Pharma network. These are stated operating objectives; they should not be read as evidence that product transfers or synergies have already been completed.

Timeline: The transaction was completed under the business transfer agreement, with the API business transfer becoming effective on 16 September 2026. ^[8] That is the stated legal/operational transfer date. A separate timetable for validation, product-by-product transfers, full capacity utilisation, or complete integration into the existing Navi Mumbai/API structure was not disclosed. The earlier reference to completion within 30 days was a pre-closing regulatory-approval timeline, not a stated schedule for post-closing integration. ^[10]

Implication: The near-term change is primarily an expansion of RPGAP’s available manufacturing platform and API portfolio. The economic benefit remains execution-dependent: it requires regulatory continuity, product transfers, customer qualification and utilisation of the additional capacity; the cited disclosures do not provide milestones or timing for those steps.